Avoid common mistakes on your manuscript.
Correction to: Diabetes Ther (2021) 12:1359–1378 https://doi.org/10.1007/s13300-021-01042-w
In the original article, Table 2 was published with an error. The correct Table 2 is given below.
Original
Table 2 Adverse drug reactions in the safety analysis population (first age category analysis) of STELLA-LONG TERM, in pre-approval clinical trials, and STELLA-ELDER
ADRs, n (%) | Pre-approval (n = 1669) [2–7] | STELLA-LONG TERM | STELLA-ELDER (n = 8505) [9] | |||
|---|---|---|---|---|---|---|
All (n = 11,051) | < 65 years (n = 7894) | ≥ 65 years (n = 3157) | P-valuea | |||
Any ADR | 549 (32.89) | 2129 (19.27) | 1528 (19.36) | 601 (19.04) | 0.701 | 1438 (16.9) |
Serious ADR | 14 (0.8) | 210 (1.90) | 122 (1.55) | 88 (2.79) | < 0.001 | 127 (1.5) |
ADRs of special interest | ||||||
Polyuria/pollakiuria | 168 (10.0) | 612 (5.54) | 471 (5.97) | 141 (4.47) | 0.002 | 170 (2.0) |
Volume depletion | 73 (4.5) | 243 (2.20) | 167 (2.12) | 76 (2.41) | 0.345 | 266 (3.1) |
Skin complications | 59 (4.0) | 198 (1.79) | 128 (1.62) | 70 (2.22) | 0.033 | 269 (3.2) |
Renal disorder | 76 (4.8) | 191 (1.73) | 119 (1.51) | 72 (2.28) | 0.005 | 118 (1.4) |
Urinary tract infection | 29 (1.8) | 170 (1.54) | 115 (1.46) | 55 (1.74) | 0.271 | 118 (1.4) |
Genital infection | 32 (2.0) | 161 (1.46) | 126 (1.60) | 35 (1.11) | 0.053 | 166 (2.0) |
Hepatic disorder | 17 (1.0) | 133 (1.20) | 110 (1.39) | 23 (0.73) | 0.004 | 19 (0.2) |
Cardiovascular disease | 16 (1.0) | 67 (0.61) | 50 (0.63) | 17 (0.54) | 0.562 | 24 (0.3) |
Hypoglycemia | 22 (1.4) | 57 (0.52) | 34 (0.43) | 23 (0.73) | 0.048 | 58 (0.7) |
Malignant tumor | 4 (0.2) | 51 (0.46) | 19 (0.24) | 32 (1.01) | < 0.001 | 11 (0.1) |
Cerebrovascular disease | 4 (0.2) | 48 (0.43) | 29 (0.37) | 19 (0.60) | 0.090 | 36 (0.4) |
Ketone body related events | 11 (1.0) | 7 (0.06) | 6 (0.08) | 1 (0.03) | –b | 2 (0.02) |
Fracture | 0 | 4 (0.04) | 4 (0.05) | 0 | –b | 2 (0.02) |
Lower limb amputation | 0 | 0 | 0 | 0 | –b | 0 |
Correct Table 2
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Nakamura, I., Maegawa, H., Tobe, K. et al. Correction to: Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM. Diabetes Ther 12, 1765–1768 (2021). https://doi.org/10.1007/s13300-021-01073-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13300-021-01073-3